Brief: Almirall Says Lebrikizumab New Phase III Study In Nummular Eczema To Start Enrolling Patients In Q2 2026
09/01/2026 16:56
Jan 9 (Reuters) - Almirall SA ALM.MC: LEBRIKIZUMAB NEW PHASE III STUDY (LUMINE) IN NUMMULAR ECZEMA (NE) EXPECTED TO START ENROLLING PATIENTS IN Q2 2026 Source text: nCNMFpBJPF Further company coverage: ALM.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24